Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Equity Ratio (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Equity Ratio data on record, last reported at 0.69 in Q4 2025.

  • For Q4 2025, Equity Ratio fell 21.75% year-over-year to 0.69; the TTM value through Dec 2025 reached 0.69, down 21.75%, while the annual FY2025 figure was 0.69, 21.75% down from the prior year.
  • Equity Ratio reached 0.69 in Q4 2025 per RVMD's latest filing, down from 0.71 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.9 in Q1 2024 and bottomed at 0.69 in Q4 2025.
  • Average Equity Ratio over 5 years is 0.84, with a median of 0.87 recorded in 2021.
  • Peak YoY movement for Equity Ratio: increased 11.44% in 2021, then decreased 21.75% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.82 in 2021, then grew by 3.36% to 0.84 in 2022, then rose by 4.96% to 0.89 in 2023, then fell by 0.04% to 0.89 in 2024, then dropped by 21.75% to 0.69 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.69 in Q4 2025, 0.71 in Q3 2025, and 0.77 in Q2 2025.